Skip to main content

Advertisement

SpringerLink
Log in

A novel bedside test for ACPA: the CCPoint test is moving the laboratory to the rheumatologist’s office

  • Mechanism in Autoimmunity
  • Published:
Immunologic Research Aims and scope Submit manuscript

An Erratum to this article was published on 13 September 2016

Abstract

Rheumatoid Arthritis (RA) is an autoimmune destructive joint disease affecting 1 % of the general population. In recent years, the benefits of identifying RA at an early stage and initiating therapy before joint damage occurs have been acknowledged. An elevated anti-citrullinated peptide antibody (ACPA) level serves as a marker for the early diagnosis of RA. Often the diagnosis is delayed because conventional methods of antibody detection require referral to a specific laboratory. In the current study, we determined the diagnostic accuracy of a new lateral flow point-of-care kit available for ACPA detection in the rheumatologist office. The presence of ACPA was determined by the visually read, qualitative rapid CCPoint® test (Euro-Diagnostica, Malmö, Sweden) compared to routinely used ELISA assays (Immunoscan CCPlus®-Euro-Diagnostica, Sweden, and QuantLite® CCP3-INOVA Diagnostics Inc., USA), in the sera of 184 patients: early RA(n = 38), established RA (n = 84), inflammatory arthritis(n = 34) and systemic lupus erythematosus (SLE) (n = 28). ACPA was detected in 18/38(47 %), 53/84(63 %), 2/34(6 %) and 2/28(7 %) of patients with early RA, established RA, inflammatory arthritis and SLE, respectively. The sensitivity and specificity, negative and positive predictive values of the CCPoint® test were equivalent to the Immunoscan CCPlus® and Quanta Lite® CCP3 ELISA assays. Correlation between ACPA positive results detected in the different assays was 97 %, while negative agreement reached 98 %. Excellent correlation (100 %) was observed between CCPoint® results obtained using capillary blood versus serum. CCPoint® is a novel technology that allows for a rapid accurate analysis of ACPA and diagnosis during the patient’s visit in the rheumatologist office.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005;4:130–6.

    Article  PubMed  Google Scholar 

  2. Raza K, Buckley CE, Salmon M, Buckley CD. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2006;20:849–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Raza K, Saber TP, Kvien TK, Tak PP, Gerlag DM. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis. 2012;71:1921–3.

    Article  PubMed  Google Scholar 

  4. van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH. What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis. 2014;73(861–870):5.

    Google Scholar 

  5. White D, Pahau H, Duggan E, Paul S, Thomas R. Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort. BMJ Open. 2013;3(7):e003083. doi:10.1136/bmjopen-2013-003083.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Suwannalai P, Britsemmer K, Knevel R, Scherer H, Levarht EW, van der Helm-van Mil AH, van Schaardenbutg D, Huizinga TW, Toes RE, Trouw LA. Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis. 2014;73:270–6.

    Article  CAS  PubMed  Google Scholar 

  7. De Cock D, Meyfroidt S, Joly J, Van der Elst K, Westhovens R, Verschueren P, on behalf of the CareRA study group. A detailed analysis of treatment delay from the onset of symptoms in early rheumatoid arthritis patients. Scand J Rheumatol. 2014;43:627–31.

    Google Scholar 

  8. Bartoloni E, Alunno A, Bistoni O, Bizzaro N, Migliorini P, Morozzi G, on behalf of the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA) investigators, et al. Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmun Rev. 2012;11:815–20.

    Article  CAS  PubMed  Google Scholar 

  9. Taylor P, Gartemann J, Hsieh J, Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factors tests for rheumatoid arthritis. Autoimmune Dis. 2012;2012:734069.

    PubMed Central  Google Scholar 

  10. Bizzaro N, Bartoloni E, Morozzi G, Manganelli S, Riccieri V, Sabatini P, for the Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA Group), et al. Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis Res Ther. 2013;15:R16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. van der Liden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH, Comparison of the 1987 American College of Rheumatology Criteria and the 2010. American college of rheumatology/European league against rheumatism criteria. Arthritis Rheum. 2011;63:37–42.

    Article  Google Scholar 

  12. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;147:797–808.

    Article  Google Scholar 

  13. Bizzaro N, Tonutti E, Tozzoli R, Villalta D. Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem. 2007;53:1527–33.

    Article  CAS  PubMed  Google Scholar 

  14. Willemze A, Toes RE, Huizinga TW, Trouw LA. New biomarkers in rheumatoid arthritis. Neth J Med. 2012;70:392–9.

    CAS  PubMed  Google Scholar 

  15. Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, et al. Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies. Clin Exp Rheumatol. 2011;29:500–5.

    CAS  PubMed  Google Scholar 

  16. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I, Gonzalez-Diaz DR, Sanchez- Ramon S, Rodriguez-Mahou M, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61:419–24.

    Article  CAS  PubMed  Google Scholar 

  17. van Dongen H, van Aken J, Lard LR, Visser K, Ronday HK, Hulsmans HM, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;56:1424–32.

    Article  PubMed  Google Scholar 

  18. Liao J, Ip WS, Cheung KY, Wan WM, Cautherley GW, Cai X, et al. Diagnostic utility of an anti-CCP point-of-care immunotest in Chinese patients with rheumatoid arthritis. Clin Chim Acta. 2011;412:778–81.

    Article  CAS  PubMed  Google Scholar 

  19. Egerer K, Feist E, Burmester GR. The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens. Dtsch Arztebl Int. 2009;106:159–63.

    PubMed  PubMed Central  Google Scholar 

  20. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580–8.

    Article  PubMed  Google Scholar 

  21. Snijders GF, Broeder AA, Bevers K, Jeurissen ME, van Eerd JE, van den Hoogen FH. Measurement characteristics of a new rapid antiCCP2 test compared to the anti-CCP2 ELISA. Scand J Rheuamtol. 2008;37:151–4.

    Article  CAS  Google Scholar 

  22. Renger F, Bang H, Feist E, Fredenhagen G, Natusch A, Backhaus M, et al. Immediate determination of ACPA and rheumatoid factor—a novel point of care test for detection of anti-MCV antibodies and rheumatoid factor using a lateral-flow immunoassay. Arthritis Res Ther. 2010;12:R120.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Rojanasantikul P, Pattrapornpisut P, Anuruckparadorn K, Katchamart W. The performance of a point of care for detection anf anti-mutated citrullinated vimentin and rheumatoid factor in early rheumatoid arthritis. Clin Rheumatol. 2014;33:919–23.

    Article  PubMed  Google Scholar 

  24. Szekanecz Z, Szabo Z, Zeher M, Soos L, Danko K, Horvath I, et al. Superior performance of the CCP3.1 test compared to CCP2 and MCV in the rheumatoid factor-negative RA population. Immunol Res. 2013;56:439–43.

    Article  CAS  PubMed  Google Scholar 

  25. Nicaise-Roland P, Noguiera L, Demattei C, de Chaisemartin L, Rincheval N, Cornillet M, et al. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Ann Rheum Dis. 2013;72:357–62.

    Article  PubMed  Google Scholar 

  26. Matsson P. Is there a future for multiplexed technologies in the point-of care setting? Bioanalysis. 2011;3:2049–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Zabludowicz Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel-Hashomer, 52621, Israel

    Gisele Zandman Goddard, Alessandra Soriano, Boris Gilburd, Ron Kopilov, Yehuda Shoenfeld & Nancy Agmon-Levin

  2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    Gisele Zandman Goddard, Merav Lidar, Shaye Kivity, Pnina Langevitz & Nancy Agmon-Levin

  3. The Zabludowicz Center for Autoimmune Diseases, Rheumatology Unit, Sheba Medical Center, Tel-Hashomer, 52621, Israel

    Merav Lidar, Shaye Kivity & Pnina Langevitz

  4. Department of Clinical Medicine and Rheumatology, Campus Bio-Medico University, Rome, Italy

    Alessandra Soriano

  5. Department of Medicine C, Wolfson Medical Center, Holon, Israel

    Gisele Zandman Goddard

  6. Incumbent of the Laura Schwarz-Kipp Chair for Research of Autoimmune Diseases, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Yehuda Shoenfeld

Authors
  1. Gisele Zandman Goddard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Soriano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Boris Gilburd
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Merav Lidar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaye Kivity
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ron Kopilov
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pnina Langevitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yehuda Shoenfeld
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nancy Agmon-Levin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nancy Agmon-Levin.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s12026-016-8858-y.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Goddard, G.Z., Soriano, A., Gilburd, B. et al. A novel bedside test for ACPA: the CCPoint test is moving the laboratory to the rheumatologist’s office. Immunol Res 65, 363–368 (2017). https://doi.org/10.1007/s12026-016-8846-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-016-8846-2

Keywords

Search

Navigation